Fundraising Fox
🦊/Companies
Sign in

Superluminal Medicines

Waltham, US · Founded 2023 · Delaware corporation · 4 known investors

Find your way into Superluminal Medicines

Biotech

Founders & leadership

CR
CATHERINE RIESENExecutive
CD
CONY D'CRUZExecutive
CR
CRAIG RANDALLNamed on SEC filing

Board

DX
DIAMANTIS XYLASBoard director
DMDYLAN MORRIS
DYLAN MORRISin𝕏Board directorManaging Director at Insight Partners
ALANDREW LEVIN
ANDREW LEVINBoard directorPartner at RA Capital
NSNANDITA SHANGARI
NANDITA SHANGARIinBoard directorManaging Director at RA Capital
HP
HARSHA PALADUGUBoard director

Investors · 4

GaingelsreportedNew York · $200K – $500K
Insight Partnersreported · 2 sourcesNew York · $120M – $350M
NVIDIAreportedSanta Clara
RA Capitalreported · 2 sourcesBostonvia Andrew Levin · board

Reported raises · per SEC filings

Form D private placements

$116.2M disclosed across 4 rounds · 2023–2026

▶$65.5MraisedSep 2026 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CONY D'CRUZExecutive Officer, Director, Promoter
  • NANDITA SHANGARIDirector
  • DYLAN MORRISDirector
  • DIAMANTIS XYLASDirector
  • HARSHA PALADUGUDirector
Offering amount
$65.5M
Amount sold
$65.5M
First sale
Aug 2026
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedAug 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DYLAN MORRISDirector
  • ANDREW LEVINDirector
  • DIAMANTIS XYLASDirector
  • CONY D'CRUZExecutive Officer, Director, Promoter
Offering amount
$5M
Amount sold
$5M
First sale
Aug 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedSep 2024 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DIAMANTIS XYLASDirector
  • DYLAN MORRISDirector
  • CATHERINE RIESENExecutive Officer
  • CONY D'CRUZExecutive Officer, Director, Promoter
  • ANDREW LEVINDirector
Offering amount
$120M
Amount sold
$20M
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.7MraisedAug 2023 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CATHERINE RIESENExecutive Officer
  • ANDREW LEVINDirector
  • CRAIG RANDALLExecutive Officer
  • CONY D'CRUZExecutive Officer, Director, Promoter
  • DYLAN MORRISDirector
Offering amount
$25.7M
Amount sold
$25.7M
First sale
Mar 2023
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugsfiercebiotech.com · Aug 2025Superluminal Medicines Closes $120M Series A Fundingfinsmes.com · Sep 2024Superluminal Medicines | Investment | Insight Partnersinsightpartners.com · Sep 2023Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeuticsglobenewswire.com · Aug 2023

Frequently asked questions

Who are Superluminal Medicines's investors?
Superluminal Medicines's investors include Gaingels, Insight Partners, NVIDIA, RA Capital.
How much funding has Superluminal Medicines raised?
Superluminal Medicines has disclosed $116.2M raised across 4 rounds.
Where is Superluminal Medicines headquartered?
Superluminal Medicines is headquartered in Waltham, US.